Report Name: Alfresa Holdings Corporation Profile – Overview, History, SWOT Analysis, Products/Services, Facts, Financials, Key Executives, Competitors, Tech Intelligence, IT Outsourcing, IT Management, Recent Developments and Strategy Evaluation
Alfresa Holdings Corporation Report – Publisher: Research Cosmos
Price Scheme of the Report:
Single User License – USD 150
Team License – USD 175
Corporate License – USD 250
Alfresa Holdings Corporation – Business Description:
Alfresa Holdings Corporation is a healthcare business group. It consists of companies engaged in the wholesale, manufacturing, marketing, and import/export of pharmaceuticals; diagnostic reagents; medical devices and equipment; and other products. The group primarily operates in Japan.
The group operates through four business segments: Ethical Pharmaceuticals Wholesaling Business, Self-Medication Products Wholesaling Business, Manufacturing Business, and Medical-Related Business.
The Ethical Pharmaceutical Wholesaling Business segment of the group is engaged in wholesale of ethical pharmaceuticals, diagnostic reagents, medical devices and equipment, and raw materials. Alfresa and its group companies distribute pharmaceuticals to medical institutions, dispensing pharmacies, drug stores, and other customers. Also, the group, through its medical care delivery system, provides customers with information on the proper use of pharmaceuticals and other products. The group operates its Ethical Pharmaceutical Wholesaling Business through subsidiaries including Alfresa Corporation, Shikoku Alfresa Corporation, TS Alfresa Corporation, Meisho Co., Odashima, Ryuyaku Co., Alfresa Medical Service Corporation, and Kowa Pharmaceuticals Co. In FY2016, the Ethical Pharmaceuticals Wholesaling Business segment reported revenues of JPY2,278,925 million, which accounted for 88.5% of the group’s total revenue.
The group sells general pharmaceuticals through its Self-Medication Products Wholesaling Business segment. The operations are carried out through its subsidiaries, Alfresa Healthcare Corporation and Mogi Pharmaceutical Co. Alfresa markets over-the-counter (OTC) pharmaceuticals, health foods, supplements, and other products to its customers such as drugstores and pharmacies. In FY2016, the Self-Medication Products Wholesaling Business segment reported revenues of JPY244,091 million, which accounted for 9.5% of the group’s total revenue.
Alfresa’s Manufacturing Business segment is engaged in the manufacture of pharmaceuticals, diagnostic reagents, medical devices and equipment. The segment provides ethical pharmaceuticals for neuropsychiatric and allergic disorders, as well as treatments for rare diseases and generic drugs. In the field of infectious diseases, Alfresa market diagnostic kits that aid rapid diagnosis in clinical and nursing settings. In the area of medical devices, the group focuses on surgical sutures, mainly for general surgery, cardiovascular surgery, and plastic surgery. Alfresa Pharma Corporation, Sannova Co., Alfresa Fine Chemical Corporation and Qingdao Nesco Medical Co. conduct the group’s manufacturing business. In FY2016, the Manufacturing Business segment reported revenues of JPY22,071 million, which accounted for 0.9% of the group’s total revenue.
The group’s Medical-Related Business segment deals with dispensing pharmacy business. The segment operates through subsidiaries including Apollo Medical Holdings and Nihon Apoch Co. In FY2016, the Medical-Related Business segment reported revenues of JPY31,317 million, which accounted for 1.1% of the group’s total revenue.
Geographically, Japan accounted for more than 90% of the group’s total revenues in FY2016.
Scope of the Report:
About the Company: Historical Details, Current Ownership Structure and basic overview of Balfour Beatty plcin terms of revenue, net income, and operating income.
Financials: Details about Balfour Beatty plclisting status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.
Products/Services: Listing of the company’s entire portfolio along with the description of individual products/services providing a clear picture of their target audience.
Company SWOT Analysis: Outlines Atea ASA.’s strengths, weaknesses, and opportunities and threats facing the company.
Recent Developments: Showcases Atea ASA.’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.
Strategic Evaluation: This section provides an overview of Atea ASA.’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.
Technology Landscape: Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken by the company at present along with outlook.
Key Questions Answered
What domain does Balfour Beatty plcoperate and what are key points about it?
What is the product/service portfolio of Atea ASA.?
How has Balfour Beatty plcperformed financially from 2013?
How does Balfour Beatty plcrank among its peers in terms of revenue and market share?
What are Balfour Beatty plcstrengths and weaknesses and what opportunities and threats do it face?
What are Atea ASA.’s main growth strategies and how successful has the company been at implementing them?
What is the in-house technical capability of Atea ASA.? Where does it procure/outsource it?
Reasons to buy
Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own
Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at a very competitive cost
12 hour delivery time fulfilling your urgent requests as per your requirement
On-demand customization options that can completely cater to your needs by focusing the report on given specifics
For More Information, Get Sample of the report:Request Sample
Got Some Questions? Inquire Here:Inquire Before Buying
Get This Report:Purchase Now
For More Details, Contact Provider Directly:
+1 888 709 8757